175 related articles for article (PubMed ID: 24844212)
1. Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene.
Baldan F; Lavarone E; Di Loreto C; Filetti S; Russo D; Damante G; Puppin C
Mol Biol Rep; 2014 Aug; 41(8):5257-65. PubMed ID: 24844212
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Baldan F; Mio C; Lavarone E; Di Loreto C; Puglisi F; Damante G; Puppin C
Oncol Rep; 2015 May; 33(5):2199-206. PubMed ID: 25812606
[TBL] [Abstract][Full Text] [Related]
3. CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.
Yang PM; Lin PJ; Chen CC
Epigenetics; 2012 Apr; 7(4):390-9. PubMed ID: 22419072
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat exhibits anticancer effects in triple-negative breast cancer cells by preventing nitric oxide-driven histone deacetylation.
Palczewski MB; Kuschman HP; Bovee R; Hickok JR; Thomas DD
Biol Chem; 2021 Mar; 402(4):501-512. PubMed ID: 33938179
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.
Maggisano V; Puppin C; Celano M; D'Agostino M; Sponziello M; Micali S; Navarra M; Damante G; Filetti S; Russo D
Endocrine; 2014 Feb; 45(1):148-52. PubMed ID: 23636804
[TBL] [Abstract][Full Text] [Related]
9. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
10. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.
Mathew OP; Ranganna K; Yatsu FM
Biomed Pharmacother; 2010 Dec; 64(10):733-40. PubMed ID: 20970954
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
[TBL] [Abstract][Full Text] [Related]
12. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
13. Vascular histone deacetylation by pharmacological HDAC inhibition.
Rafehi H; Balcerczyk A; Lunke S; Kaspi A; Ziemann M; Kn H; Okabe J; Khurana I; Ooi J; Khan AW; Du XJ; Chang L; Haviv I; Keating ST; Karagiannis TC; El-Osta A
Genome Res; 2014 Aug; 24(8):1271-84. PubMed ID: 24732587
[TBL] [Abstract][Full Text] [Related]
14. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells.
Wu Q; Xu W; Cao L; Li X; He T; Wu Z; Li W
J Proteome Res; 2013 Sep; 12(9):4064-73. PubMed ID: 23909948
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
16. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
17. Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.
Liu Z; Xing M
PLoS One; 2012; 7(2):e31729. PubMed ID: 22359623
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.
Dudakovic A; Evans JM; Li Y; Middha S; McGee-Lawrence ME; van Wijnen AJ; Westendorf JJ
J Biol Chem; 2013 Oct; 288(40):28783-91. PubMed ID: 23940046
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]